VCBeat has learned that Shengna Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Shengna Technology”) has completed its Pre-A financing round, raising tens of millions of yuan. The round was led by FIRHealth Capital. The funds raised will be used for the clinical trial research and regulatory filings of the company’s small-diameter artificial vascular products, as well as to accelerate the clinical translation of its globally leading bio-micro/nanomaterial technology.China has over 100 million patients with chronic renal failure, and more than one million individuals undergo hemodialysis. Small-diameter synthetic vascular grafts play a crucial role in establishing hemodialysis access for patients with end-stage renal disease, directly impacting their survival and quality of life. Currently, the Chinese market for synthetic vascular grafts remains dominated by foreign brands, particularly for small-diameter grafts with diameters less than 6 mm. Due to high rates of restenosis, no domestically produced product has yet been successfully applied in clinical practice, making domestic substitution an urgent priority.By leveraging globally leading electrospinning technology for micro- and nanofibers, Shengna Technology has successfully achieved large-scale production of small-diameter artificial vascular grafts using micro- and nanomaterials. This product is at the forefront of global innovation, featuring core properties such as anticoagulation and immediate cannulation capability that enable it to compete with leading international products. Furthermore, it offers superior mechanical performance, reduced risk of bleeding, and shorter hemostasis time. The technology is poised to overcome critical bottlenecks in this field, fill the gap in domestically produced clinical solutions, and benefit a broader patient population. Meanwhile, the preparation and processing technologies for medical micro- and nanomaterials also hold vast application potential in fields such as medical aesthetics and wound dressings.Shengna Technology - Professor Li Song, Chief Scientific Advisor“Shengna Technology holds broad prospects for applications and innovation in the field of biomaterials and manufacturing. We believe that investments from FIRHealth Capital and other funds will promote the clinical application and further innovation of bio-micro/nanomaterials. In the future, we will continue to build Shengna Technology into a globally leading platform for bio-micro/nanotechnology, deepen our expertise in the field of bio-micro/nanomaterials, accelerate preclinical research and clinical development across our product pipelines, and strive to bring more innovative medical devices that address unmet clinical needs to patients.”Lead Investor – Huang Xiaobin, Founder of FIRHealth Capital“The development cycle for small-diameter artificial blood vessels is long, with high technical barriers and significant manufacturing challenges. Long-term implantation and repeated punctures impose stringent requirements on the material’s biocompatibility, mechanical properties, and long-term patency rates. Shengna Technology has creatively introduced micro- and nanotechnology into this field and successfully achieved industrial-scale mass production. Its product represents a truly original innovative medical device and holds a leading position globally. We look forward to the Shengna Technology team achieving continuous breakthroughs in subsequent clinical development, thereby benefiting patients at large as soon as possible.”
Shengna Technology was founded in 2015 by Professor Li Song, an internationally renowned expert in biomedical materials and former Chair of the Department of Bioengineering at the University of California, Los Angeles (UCLA), together with Dr. Dai Weimin, a prominent entrepreneur and President of the UC Berkeley Shanghai Alumni Association, with support from the Zhangjiang Berkeley Innovation Center. The company focuses on the development and application of bio-micro/nanotechnology in high-value medical devices and new materials. Shengna Technology has established a leading platform for the application and clinical translation of bio-micro/nanotechnology, developing a series of products based on bio-micro/nanomaterials. Its small-diameter artificial blood vessels feature outstanding performance advantages, including anticoagulation, kink resistance, and immediate puncture capability, holding promise to break the monopoly of foreign brands in this field. In the future, Shengna Technology will expand the application of bio-micro/nanomaterials into more areas leveraging its innovative materials, modification technologies, and production processes.
FIRHealth Capital, established in 2021, is an emerging investment fund specializing in the biopharmaceutical and broader healthcare sectors. The firm focuses on innovative investments and value discovery within the global biopharmaceutical industry. Its team comprises high-caliber professionals from the industrial, scientific research, and venture capital communities, bringing extensive experience in both the pharmaceutical industry and investment. Adhering to its core philosophy of “seeking truth and being pragmatic, and dedicating meticulous effort and wisdom,” FIRHealth Capital maintains investment principles of “foresight and independence.” It is committed to creating sustainable value for investors, shareholders, and society at large through rigorous project evaluation and scientific investment decision-making. As a dedicated specialist in the healthcare sector, FIRHealth Capital not only pursues successful investments and returns but also strives to advance medical technology and improve human health. By partnering with outstanding scientists and entrepreneurs, the firm remains true to its original aspiration, jointly writing a new chapter in life sciences. 
